topics
news report
An NIH-funded study of more than 1,200 people found 34 circular RNAs predicted progression better than a leading protein marker, but no clinical assay is yet available.
news report
Orzeyful, or oveporexton, is the first approved medicine designed to restore the missing wakefulness signal behind the disorder’s full symptom pattern.
news report
Tregzi improved one-year chronic GVHD-free survival to 78% in a randomized trial of 187 adults, compared with 38.4% after a standard transplant.
news report
A 1,173-person NIH trial found a 21% lower risk of developing two chronic conditions; metformin did not significantly reduce that outcome.